Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fx-5A peptide complex
- Development stage
- Phase 1
- Lead developer
- KineMed
- Modality
- Peptide Conjugates → Peptides, Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Fx-5A peptide complex is a High Density Lipoprotein (HDL) mimetic designed to treat cardiovascular diseases and inflammation. It combines a bihelical ApoA-I mimetic peptide (5A peptide) with sphingomyelin to create a peptide-lipid complex that specifically effluxes cholesterol via the ABCA1 transporter, enhancing the first step in the reverse cholesterol transport pathway. The complex has demonstrated ability to reduce atherosclerosis in preclinical models and exhibits anti-inflammatory and antioxidant properties.
02
Targets
ABCA1 (ATP-binding cassette transporter A1)APOA1 (Apolipoprotein A-I)
Beyond the preview
Go deeper on Fx-5A peptide complex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fx-5A peptide complex.